Search Results

Who is at risk?

References Depression and anxiety disorders CHAPTER 3 References Furukawa TA, et al. Meta-­analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. BMJ 2002; 325:991. Donoghue J, et al. Suboptimal use of a...

What is the mechanism? Depression and anxiety disorders CHAPTER 3 References Schieveld JNM, et al. On benzodiazepines, paradoxical agitation, hyperactive delirium, and chloride homeostasis. Crit Care Med 2018; 46:1558–1559. Dietch JT, et al. Aggressive dyscon...

Subjective reports

Clinical implications 474 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 3 Premenstrual syndrome Premenstrual syndrome (PMS) is a collection of mood and physical symptoms occurring during the luteal phase of the menstrual cycle. There are several d...

References Depression and anxiety disorders CHAPTER 3 If COCPs are ineffective, not tolerated, or contraindicated, a second-­line approach is to prescribe continuous percutaneous bioidentical estradiol (i.e. implants or transdermal preparations).9 In patients ...

Drug treatment of depression 344 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 3 Drug treatment of depression Drugs used in the treatment of depression are summarised in Figure 3.1. Discuss choice of drug with the patient No effect No effect Effec...

Notes Depression and anxiety disorders CHAPTER 3 Notes ■ ■Tools such as the Montgomery–Asberg Depression Rating Scale (MADRS)12 and the HAM-­D13 are used in trials to assess drug effect. The HAM-­D is now somewhat anachronistic and few clinicians are familiar ...

References 346 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 3 in treatment (British Association for Psychopharmacology guidelines suggest 4 weeks).3 If there is some improvement at this time, continue and assess for a further 2–3 weeks (see secti...

Management of treatment-resistant depression – commonly used treatments 348 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 3 Management of treatment-­resistant depression – commonly used treatments Resistant depression is difficult to treat success...

References Depression and anxiety disorders CHAPTER 3 References Dunner DL, et al. Prospective, long-­term, multicenter study of the naturalistic outcomes of patients with treatment-­resistant depression. J Clin Psychiatry 2006; 67:688–695. Wooderson SC, et  ...

Management of treatment-resistant depression – other well- supported treatments Depression and anxiety disorders CHAPTER 3 Management of treatment-­resistant depression – other wellsupported treatments Less commonly used treatments for treatment-­resistant dep...

References 352 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 3 References Marcantoni WS, et al. A systematic review and meta-­analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 – January 201...

Treatment-resistant depression – other reported treatments Depression and anxiety disorders CHAPTER 3 Treatment-­resistant depression – other reported treatments A very wide range of treatments have been investigated as potential therapy for treatment-­resista...

References 354 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 3 References Gonçalves J, et al. A systematic review on the therapeutic effects of ayahuasca. Plants (Basel) 2023; 12:2573. Stanciu CN, et  al. Use of buprenorphine in treatment of refr...

Ketamine

Background

Mechanism